Biliary Tract Disorders in Patients with Acromegaly: Single-centre Experience

Objective: Genetic and environmental factors determine the risk of biliary tract disorders. Several studies have reported an increased frequency of gallbladder disorders in patients with acromegaly belonging to different ethnic groups, however, data for Turkish patients with acromegaly is currently lacking. The primary objective of this study was to evaluate the frequency of diverse gallbladder disorders in Turkish patients with acromegaly. The secondary objective was to determine the risk factors that are related to gallstone formation. Materials and Methods: Hacettepe University electronic database was retrospectively analyzed. One hundred fifty-two out of 393 patients with acromegaly who had confirmed biliary tract disorders with imaging modalities (such as abdominal ultrasonography, abdominal computed tomography or abdominal magnetic resonance imaging) or surgery specimens, were included for final analyzes. There was not any difference between included and excluded cases in terms of study parameters. Results: Patients with acromegaly with a mean±SD age of 41±12 years were followed-up for median of 91 months. Gender distribution was equal (76 M, 76 F). Gallstones were detected in 50 (33%) cases. Seventeen (11%) cases had gallbladder sludge whereas 5 (3%) cases had gallbladder polyp. Cholecystectomy was performed in 24 (16%). Age, gender, baseline disease activity, diagnostic delay, disease duration, the presence of type 2 diabetes mellitus and hyperlipidemia were not associated with gallstone formation. Body mass index (β=1.19, 95% CI (1.09-1.30), p

PDF

___

[1] Katznelson L, Laws ER, Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of clinical endocrinology and metabolism 2014;99(11):3933- 51. doi: 10.1210/jc.2014-2700
[2] Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine reviews 2004;25(1):102-52. doi: 10.1210/er.2002-0022
[3] Renehan AG, Painter JE, Bell GD, Rowland RS, O’Dwyer ST, Shalet SM. Determination of large bowel length and loop complexity in patients with acromegaly undergoing screening colonoscopy. Clinical endocrinology 2005;62(3):323-30. doi: 10.1111/j.1365-2265.2005.02217.x
[4] Rokkas T, Pistiolas D, Sechopoulos P, Margantinis G, Koukoulis G. Risk of colorectal neoplasm in patients with acromegaly: a meta-analysis. World journal of gastroenterology 2008;14(22):3484-9. doi: 10.3748/ wjg.14.3484
[5] Wassenaar MJ, Cazemier M, Biermasz NR, et al. Acromegaly is associated with an increased prevalence of colonic diverticula: a case-control study. The Journal of clinical endocrinology and metabolism 2010;95(5):2073-9. doi: 10.1210/jc.2009-1714
[6] Baris D, Gridley G, Ron E, et al. Acromegaly and cancer risk: a cohort study in Sweden and Denmark. Cancer causes & control : CCC 2002;13(5):395-400. doi: 10.1023/a:1015713732717
[7] Annamalai AK, Gayton EL, Webb A, et al. Increased prevalence of gallbladder polyps in acromegaly. The Journal of clinical endocrinology and metabolism 2011;96(7):E1120-5. doi: 10.1210/jc.2010-2669
[8] Aapkes SE, de Haas RJ, Bernts LHP, et al. Incident Gallstones During Somatostatin Analog Treatment are Associated with Acute Biliary Complications Especially After Discontinuation. Drugs in R&D 2021;21(2):179-88. doi: 10.1007/s40268-021-00342-7
[9] Grasso LF, Auriemma RS, Pivonello R, Colao A. Adverse events associated with somatostatin analogs in acromegaly. Expert opinion on drug safety 2015;14(8):1213-26. doi: 10.1517/14740338.2015.1059817
[10] Prencipe N, Bona C, Cuboni D, et al. Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment. Pituitary 2021;24(2):242-51. doi: 10.1007/ s11102-020-01102-7
[11] Lammert F, Gurusamy K, Ko CW, et al. Gallstones. Nature reviews. Disease primers 2016;2:16024. doi: 10.1038/ nrdp.2016.24
[12] Aerts R, Penninckx F. The burden of gallstone disease in Europe. Alimentary pharmacology & therapeutics 2003;18 Suppl 3:49-53. doi: 10.1046/j.0953-0673.2003.01721.x
[13] Everhart JE, Khare M, Hill M, Maurer KR. Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology 1999;117(3):632-9. doi: 10.1016/ s0016-5085(99)70456-7
[14] Miquel JF, Covarrubias C, Villaroel L, et al. Genetic epidemiology of cholesterol cholelithiasis among Chilean Hispanics, Amerindians, and Maoris. Gastroenterology 1998;115(4):937-46. doi: 10.1016/s0016-5085(98)70266-5
[15] Karayalçin R, Genç V, Karaca AS, Özakşıt G. Prevalence of cholelithiasis in a Turkish population sample of postmenopausal women. The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 2010;21(4):416-20
[16] Boyer JL, Soroka CJ. Bile formation and secretion: An update. Journal of hepatology 2021;75(1):190-201. doi: 10.1016/j.jhep.2021.02.011
[17] Hundt M, Basit H, John S. Physiology, Bile Secretion. StatPearls. Treasure Island (FL): StatPearls Publishing; 2022. [18] Lyons MA, Wittenburg H. Cholesterol gallstone susceptibility loci: a mouse map, candidate gene evaluation, and guide to human LITH genes. Gastroenterology 2006;131(6):1943-70. doi: 10.1053/j. gastro.2006.10.024
[19] Nepokroeff CM, Lakshmanan MR, Ness GC, Dugan RE, Porter JW. Regulation of the diurnal rhythm of rat liver beta-hydroxy-beta-methylglutaryl coenzmye A reductase activity by insulin, glucagon, cyclic AMP and hydrocortisone. Archives of biochemistry and biophysics 1974;160(2):387-96. doi: 10.1016/0003-9861(74)90412-3
[20] Chait A, Bierman EL, Albers JJ. Low-density lipoprotein receptor activity in cultured human skin fibroblasts. Mechanism of insulin-induced stimulation. The Journal of clinical investigation 1979;64(5):1309-19. doi: 10.1172/ jci109587
[21] Subbiah MT, Yunker RL. Cholesterol 7 alpha-hydroxylase of rat liver: an insulin sensitive enzyme. Biochemical and biophysical research communications 1984;124(3):896- 902. doi: 10.1016/0006-291x(84)91042-8
[22] Qatanani M, Lazar MA. Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes & development 2007;21(12):1443-55. doi: 10.1101/ gad.1550907
[23] Méndez-Sánchez N, Chavez-Tapia NC, Motola-Kuba D, et al. Metabolic syndrome as a risk factor for gallstone disease. World journal of gastroenterology 2005;11(11):1653-7. doi: 10.3748/wjg.v11.i11.1653
[24] Tsai CJ, Leitzmann MF, Willett WC, Giovannucci EL. Central adiposity, regional fat distribution, and the risk of cholecystectomy in women. Gut 2006;55(5):708-14. doi: 10.1136/gut.2005.076133
[25] Paragliola RM, Corsello SM, Salvatori R. Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary 2017;20(1):109-15. doi: 10.1007/s11102-016-0768-4
[26] Gomes-Porras M, Cárdenas-Salas J, Álvarez-Escolá C. Somatostatin Analogs in Clinical Practice: a Review. International journal of molecular sciences 2020;21(5). doi: 10.3390/ijms21051682
[27] Shamsi BH, Chatoo M, Xu XK, Xu X, Chen XQ. Versatile Functions of Somatostatin and Somatostatin Receptors in the Gastrointestinal System. Frontiers in endocrinology 2021;12:652363. doi: 10.3389/fendo.2021.652363
[28] Lembcke B, Creutzfeldt W, Schleser S, Ebert R, Shaw C, Koop I. Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men. Digestion 1987;36(2):108-24. doi: 10.1159/000199408
[29] Fisher RS, Rock E, Levin G, Malmud L. Effects of somatostatin on gallbladder emptying. Gastroenterology 1987;92(4):885-90. doi: 10.1016/0016-5085(87)90961-9
[30] Gong AY, Tietz PS, Muff MA, et al. Somatostatin stimulates ductal bile absorption and inhibits ductal bile secretion in mice via SSTR2 on cholangiocytes. American journal of physiology. Cell physiology 2003;284(5):C1205-14. doi: 10.1152/ajpcell.00313.2002
[31] Moschetta A, Stolk MF, Rehfeld JF, et al. Severe impairment of postprandial cholecystokinin release and gall-bladder emptying and high risk of gallstone formation in acromegalic patients during Sandostatin LAR. Alimentary pharmacology & therapeutics 2001;15(2):181-5. doi: 10.1046/j.1365-2036.2001.00924.x
[32] Attanasio R, Mainolfi A, Grimaldi F, et al. Somatostatin analogs and gallstones: a retrospective survey on a large series of acromegalic patients. Journal of endocrinological investigation 2008;31(8):704-10. doi: 10.1007/bf03346419
[33] Brighi N, Lamberti G, Maggio I, et al. Biliary stone disease in patients receiving somatostatin analogs for neuroendocrine neoplasms. A retrospective observational study. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 2019;51(5):689-94. doi: 10.1016/j.dld.2018.09.013